House Rep. Frank Pallone Jr. and Sen. Bernie Sanders sent a letter to FDA Commissioner Marty Makary expressing 'deep concerns' about the Commissioner's National Priority Voucher (CNPV) program, citing lack of congressional authorization, limited transparency, and the risk of political favoritism. The CPNV program grants winners compressed review timelines — one- to two-month reviews — and has already named 15 recipients, including large pharma firms. Lawmakers urged the FDA to justify criteria, disclose selection processes, and address potential conflicts of interest. The probe could prompt policy clarification or legislative oversight and adds regulatory risk to companies relying on expedited non-statutory review paths.